Wall Street Os Positive on Jazz Pharmaceuticals PLC (JAZZ). On Average, Analysts Give JAZZ a Strong Buy Rating. The Average Price Target is $160.571, Which Means Analysts Expect the Stock to Rise by 40.94% Over the Next Twelve Months .